Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Trop Med Hyg ; 103(2): 756-759, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32394887

RESUMEN

Clinical failure of primaquine (PQ) has been demonstrated in people with CYP450 2D6 genetic polymorphisms that result in reduced or no enzyme activity. The distribution of CYP2D6 genotypes and predicted phenotypes in the Cambodian population is not well described. Surveys in other Asian countries have shown an approximate 50% prevalence of the reduced activity CYP2D6 allele *10, which could translate into increased risk of PQ radical cure failure and repeated relapses, making interruption of transmission and malaria elimination difficult to achieve. We determined CYP2D6 genotypes from 96 volunteers from Oddor Meanchey Province, Cambodia, an area endemic for Plasmodium vivax. We found a 54.2% frequency of the *10 allele, but in approximately half of our subjects, it was paired with a normal activity allele, either *1 or *2. The prevalence of *5, a null allele, was 9.4%. Overall predicted phenotype percentages were normal metabolizers, 46%; intermediate metabolizers, 52%; and poor metabolizers, 1%.


Asunto(s)
Antimaláricos/uso terapéutico , Citocromo P-450 CYP2D6/genética , Malaria Vivax/tratamiento farmacológico , Primaquina/uso terapéutico , Artemisininas/uso terapéutico , Pueblo Asiatico/genética , Cambodia , Quimioterapia Combinada , Enfermedades Endémicas , Frecuencia de los Genes , Genotipo , Humanos , Variantes Farmacogenómicas , Fenotipo , Plasmodium vivax , Polimorfismo Genético , Quinolinas/uso terapéutico , Recurrencia , Insuficiencia del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA